Cryoport, Inc.

Cryoport, Inc.

CYRXNYSE / NASDAQIndustrialsSmall cap

$19.05-$0.50 (-2.6%)

Last close · Data as of Nov 20, 2026

Market cap
$814.5M
P/E
10.4x
EV / EBITDA
-379.0x
Revenue
$176.2M
Net margin
44.4%
ROCE
-6.7%

+127.6% over the last year

Cryoport, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+9.2%
3M
+14.0%
6M
+35.4%
1Y
+127.6%
5Y
-73.6%

52-week range

Day change -$0.50 (-2.6%) from $20 to $19 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in CYRX, bought on each weekday since 2021.

News & filings

What Cryoport filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernOperating cash flow was -8.6 million US dollars in fiscal 2025, a year of net profit.

Strengths (1)

  • Return on equity rose from -31.2% to 17.0% between fiscal 2024 and fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry.

Read moreShow less

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.

Sector
Industrials
Shares outstanding
55.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$814.5M
P/E
10.4x
P/B
1.8x
EV / EBITDA
-379.0x
EV / Sales
4.5x
P/S
4.6x
52-week high
$20.74
52-week low
$7.72

Profitability

Operating margin
-20.9%
Net margin
44.4%
EBITDA margin
-1.2%
ROE
17.0%
ROCE
-6.7%
ROIC
-4.9%
ROA
10.2%
Asset turnover
0.23

Growth

Revenue
$176.2M
Revenue growth, 1Y
12.4%
Revenue CAGR, 3Y
-9.4%
Net profit growth, 1Y
-168.2%
Free cash flow
-$28.1M

Solvency

Current ratio
2.17
Debt / Equity
0.50
Debt / Assets
0.30
CFO / Net profit
-0.11
Cash / Market cap
30.8%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$176.2M
Cost of revenue$93.1M
Gross profit$83.1M
Operating expenses$119.9M
Research and development$17.0M
Selling, general and administrative$102.8M
Operating income-$36.8M
Interest and other$4.6M
Pretax income-$32.2M
Tax and other-$110.5M
Net income$78.3M

Revenue and net profit

Revenue grew 12.4% in FY2025; net profit is the dashed line.

Cryoport, Inc. revenue and net profit by fiscal year
Cryoport, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$237.3M-$37.3M
FY2023$168.7M-$99.6M
FY2024$156.8M-$114.8M
FY2025$176.2M$78.3M

Cash flows

FY2025: -$8.6M from operations, -$28.1M free after investment (dashed).

Cryoport, Inc. operating and free cash flow by fiscal year
Cryoport, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$1.9M-$26.0M
FY2023-$757.0k-$45.7M
FY2024-$16.3M-$37.6M
FY2025-$8.6M-$28.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$176.2M+12.4%1Y
EBITDA
-$2.1M
Net profit
$78.3M
Cash from operations
-$8.6M
Free cash flow
-$28.1M
Revenue CAGR, 3Y
-9.4%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$176.2M-$2.1M$78.3M-$28.1M17.0%+12.4%-168.2%

Monthly returns

Month-by-month returns of CYRX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$765.0M
Liabilities$262.4M
Equity$502.6M
Paid-in capital$1.2B
Retained earnings-$688.9M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Industrials companies placed by value, growth and quality; CYRX highlighted.

P/E against peers

CYRX trades at 10.4x earnings against a peer median of -3.4x.

  1. Cryoport, Inc. (this company)10.4x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Cryoport, Inc.CYRXthis company$814.5M10.4x1.8x17.0%-379.0x
Mayville Engineering Company, Inc.MEC$833.1M-102.7x3.5x-3.4%28.5x
Quanex Building Products CorporationNX$818.2M-3.3x1.1x-34.5%-19.1x
Compass DiversifiedCODI$802.8M-3.5x-22.4x632.3%164.9x
Montrose Environmental Group, Inc.MEG$800.8M-949.9x1.8x-0.2%14.1x
Barrett Business Services, Inc.BBSI$798.2M14.7x3.3x22.6%8.3x
Apogee Enterprises, Inc.APOG$797.9M14.7x1.6x10.6%7.4x
Matthews International CorporationMATW$796.0M-32.5x1.7x-5.1%10.1x
Spire Global, Inc.SPIR$775.8M15.1x6.9x45.4%9.1x
Peer median—-3.4x1.7x5.2%9.6x

Year-to-date ROI

CYRX since 1 January, against earlier years.

Historical volatility

CYRX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Cryoport, Inc. operating margin by fiscal year
Cryoport, Inc. operating margin by fiscal year
DateOperating margin
FY2022-13.4%
FY2023-30.2%
FY2024-36.9%
FY2025-20.9%
LineFY2025
Cost of revenueCost Of Revenue$93.1M
Gross profitGross Profit$83.0M
Operating expensesOperating Expense$119.9M
Research and developmentResearch And Development$17.0M
Selling, general and administrativeSelling General And Administration$102.8M
Total expensesTotal Expenses$213.0M
Pretax incomePretax Income-$32.2M

Learn while you research

Academy chapters picked for Cryoport, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 10.4 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Business Cycles & StocksThese cyclical sectors win and lose in different macro phases.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →